Navigation Links
Paramount Acquisition Corp. Files Amendment to Preliminary Proxy Statement for Proposed Acquisition of Chem Rx
Date:9/27/2007

ernet site http://www.sec.gov or by directing a request to Paramount Acquisition Corp., 787 7th Avenue, 48th Floor, New York, NY 10019. As a result of the review by the SEC of the preliminary proxy statement, Paramount may be required to make changes to its description of Chem Rx's business or other information contained in the proxy statement.

Paramount, Chem Rx and their respective officers and directors may be deemed to be participants in the solicitation of proxies from Paramount's stockholders with respect to the transaction. More detailed information regarding the direct and indirect interests of Paramount, Chem Rx and their respective officers and directors in the proposed transaction are included in the proxy statement.

Contacts:

J. Jay Lobell Stephanie Carrington / Elizabeth Scott

Chief Executive Officer & The Ruth Group

Secretary 646-536- 7017 / 7014

Paramount Acquisition Corp. scarrington@theruthgroup.com

(212) 554-4522 escott@theruthgroup.com

jlobell@paramountbio.com


'/>"/>
SOURCE Paramount Acquisition Corp.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
2. Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
3. NHS financial crisis may lead to roll back of flexi-work scheme and private acquisition
4. Smoking Increases Risk of HIV Acquisition
5. Roche Completes Acquisition of BioVeris
6. Circassia Announces Acquisition of Organ Transplant Anti-Rejection Technology
7. Oracle Corp. to help build worlds first "Digital Hospital"
8. Novartis files application with FDA for Zometa
9. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
10. Unfavourable Lipid-Lipoprotein profiles in older adults has been linked to abdominal visceral fat
11. Understanding Gene Profiles Could Help Cure A Resistant Form Of Leukemia In Kids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)...POLIS, May 15 /PRNewswire-FirstCall/ -- Lung cance...ent decisions may fare better as a,result, accordi...er (NSCLC),clinical trial. Data from the trial, wh...metrexed for injection), will be presented at the ...nical Oncology (ASCO) in Chicago,Ill., May 30 -- ...
(Date:5/15/2008)...n, DC -- With the goal of tailoring cancer treatme...University Medical Center today presented a study ...re reliably assess treatment efficacy for patients...veral weeks and sometimes months to determine if a... can take that long to observe any significant rad...
(Date:5/15/2008)...USTON - Celecoxib, the anti-inflammatory medicatio...n to be safe and reduces a specific proliferation ...ccording to a study from The University of Texas M...ates the significance of COX-2 inhibition toward p...k of developing the disease. , The study is the ...
(Date:5/15/2008)..., China, May 15 /Xinhua-PRNewswire-FirstCall/ -- G...etin Board: GTEC) ("Genesis" or,the "Company"), a ...rations,in the People,s Republic of China, today a...ed March 31, 2008, the Company,s third quarter of ...was filed for the quarter,with the U.S. Securities...
Breaking Medicine News(10 mins):Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 2Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 3Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 4Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 5Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 6Health News:ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection) 7Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 3Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 2Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 3Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 4Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 5Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 6Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 7Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 8Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 9Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 10Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 11Health News:Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008 12
...esearch and Learning Disabilities and Prof. Baruch...niversity of Haifa have developed a standardized t...lities. The project was headed by Prof. Zvia Bre...Brain Research and Learning Disabilities at the Un...
...ducing obesity among American consumers, but some ...beneficial in the battle against the bulge accordi...hed monthly by the Institute of Food Technologists...cent food science, nutrition and metabolic researc...
...y provide effective protection against HIV was wel...HO) and the UNAIDS Secretariat. It follows public...Kenya and Uganda in the medical journal The Lancet...er study by the South Africa Orange Farm Intervent...
...n-one fixed dose combination Atripla in 66 develop...th Organization prequalification for the product, ...is a single tablet containing a daily dose of efav...ll be priced at $613 a year for least developed co...
Other Medicine News:Health News:Standardized Diagnostic Test for Learning Disabilities 2Health News:Merck Announces Plans for Licensing Atripla Widely in Developing World 2
(Date:5/15/2008)...leared device to identify the, lipid core (fatty)...with complications of coronary s...- InfraReDx, Inc. today,announced that physicians ...cessfully used its LipiScan(TM) Coronary Imaging S...ation. This is the first patient in the,world in w...
(Date:5/15/2008).../ -- Tigris Pharmaceuticals,Inc. announced today ...pment Agreement (CRADA) with the National Cancer I...linical development of AFP-464, an,aminoflavone cu...ed to,metabolites which bind covalently to DNA, re... part of a four-year CRADA encompassing multiple P...
(Date:5/15/2008)...l data reports in third quarter ...ire-FirstCall/ -- VIA Pharmaceuticals,Inc. (Nasda... development of,compounds for the treatment of car...ompleted patient enrollment in its acute coronary ...e Phase 2 trials investigating VIA-2291,the compa...
(Date:5/14/2008)...FirstCall/ -- Progen,Pharmaceuticals Limited (ASX:...y has resumed patient enrolment in the phase 1 dos...ine analogue, PG-11047 (formerly CGC-11047),for pa...d development of PG-11047 - the lead clinical,comp...g its acquisition of,Cellgate, Inc earlier this ye...
Breaking Medicine Technology:First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047 2Novel method to reveal drug targets 12458 1Novel method to reveal drug targets 12458 2Novel method to reveal drug targets 12458 3John OConnell Joins Finesse Solutions as Vice President of Sales and Business Development 12453 1Wyeths XYNTHA Approved by FDA for Treatment of Hemophilia A 12448 1Wyeths XYNTHA Approved by FDA for Treatment of Hemophilia A 12448 2Wyeths XYNTHA Approved by FDA for Treatment of Hemophilia A 12448 3Wyeths XYNTHA Approved by FDA for Treatment of Hemophilia A 12448 4U S Court Approves AK Steels VEBA Health Care Settlement With Middletown Works Retirees 12444 1U S Court Approves AK Steels VEBA Health Care Settlement With Middletown Works Retirees 12444 2
...HAMBURG, Germany, May 03, 2007 /PRNewswire/ -- At ... data which provide a sound,scientific basis for a...n patients. , Tumor tissue-derived primary cell li... testing. During their clonal selection and,expans...tterns,change significantly, thereby losing many o...
...BOSTON, May 03, 2007 /PRNewswire/ -- Bayer HealthC... three clinical,studies with Betaseron(R) (interfe...Academy of Neurology,s (AAN) 59th Annual Meeting,...ty, and high,patient satisfaction with treatment i...sis (MS). , "Collectively, these studies highlight...
Other Medicine Technology:Indivumed Study Provides Sound Scientific Basis for a Predictive,Drug Test- Platform 2Studies Presented at Neurology Conference Highlight Early Efficacy,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron 2Studies Presented at Neurology Conference Highlight Early Efficacy,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron 3Studies Presented at Neurology Conference Highlight Early Efficacy,Long-Term Tolerability, and High Patient Satisfaction with,Betaseron 4
Black Spandex Above the Knee Compression Girdles with Hook & Eye with Zipper
Short Girdle, High Waist, Mid-thigh
Male Body Shaper, Front Closure
Uniform compression and support after multiple procedures. No uncomfortable waist band.
Medicine Products: